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Abstract: Until the last century, infectious diseases were the leading cause of human 
mortality. Therefore, our current medical reasoning is profoundly influenced by views that 
originated from medical microbiology. The notion that cancer growth is sustained by a sub-
population of particular cells, the cancer stem cells, is highly reminiscent of the germ theory 
of disease as exemplified by Koch’s postulates in the XIXth century. However, accumulating 
data underscore the importance of cell-cell interactions and tumor environment. Hence it is 
essential to critically review the basic tenets of the cancer stem cell concept on the light of 
their relationships with Koch’s postulates. Shifting the pathogenic element from a special 
cellular entity (cancer stem cell or microorganism) to a “pathogenic field” could be critical for 
curing both cancer and drug-resistant infectious diseases. 
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Introduction. 
In recent years, accumulating experimental evidence has been presented demonstrating that 
solid tumor growth is driven by a small subset of cancer cells, the cancer stem cells [1-3]. 
These cells are defined as self-renewing cells responsible for maintaining cancer growth and 
for producing differentiated progeny that form the bulk of the tumor [4].  The cancer stem cell 
concept has an immediate therapeutic consequence: if cancer growth is sustained exclusively 
by rare cancer stem cells, then curative therapy will require targeting this cell population. 
Therefore, it is critical to fully characterize these cells. Cancer stem cells can be prospectively 
isolated by flow cytometry on their ability to outflow Hoechst 33342 (SP phenotype) or on the 
basis of cell surface markers expression [5-13]. For example, the cancer stem cell population 
is defined as CD133
+
 in brain tumors [5], CD133
+
 [6,7] or EpCAMhigh/CD44
+
/CD166
+
 in 
colon cancer [8],  CD44
+
/CD24
-/low
/Lineage
-
  in breast tumors [9], and CD44
+
/CD117
+
 in 
ovarian tumors [10].  The experimental procedure to identify cancer stem cells is: i) their 
isolation from patients, ii) their growth or selection in pure culture and, iii) serial reproduction 
of the disease by their inoculation into animals (experimental tumors should be a phenocopy 
of the original tumor) (Fig. 1A). Nevertheless, although subpopulations of tumorigenic cancer 
cells with self-renewal and differentiation capacities have been characterized in leukaemia 
and several solid tumors, the cancer stem cell concept remains controversial [14-18]. Indeed, 
recent data have raised concerns about the use of Hoechst dye exclusion to define cancer stem 
cells [19-23], and CD133 negative cells have recently been described as tumorigenic in brain 
and colon tumors [24-26].   
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Fig 1 
Cancer stem cell and Koch’s postulates. 
Experimental steps, used to characterize cancer stem cells, follow the logic diagram used to 
establish a causal relationship between a bacteria and a disease. However, are cancer and 
infectious diseases bio-logically equivalent?  
 
 
Koch’s postulates. 
Koch’s postulates were derived in the late 19th century from work on infectious diseases, and 
then they have been extensively used for proving disease causation by microbes. The three 
basic principles of Koch’s postulates, as they have been presented in 1890 before the Tenth 
International Congress of Medicine in Berlin can be summarized as shown in Box 1 [27-29].  
However, although Koch’s postulates were devised as general guidelines to identify infectious 
microbes, these criteria have several limitations, some of them already noticed by Koch 
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himself.  Thus, polymicrobial infections do not comply with Koch’s principles [30]. Other 
well-known examples of Koch’s postulates limitations are when the pathogenic 
microorganism cannot be grown in pure culture [31], or when there is no animal model for the 
corresponding infection [28]. These limitations must be noticed as Koch’s postulates are still 
sometimes implicitly used for determining causation in medicine. Indeed, as previously noted 
by Fredricks and Relman, “in certain diseases, the blind adherence to Koch’s postulates may 
act as an hindrance instead of an aid” [28].  
 
   
 
Koch’s postulates and cancer stem cell. 
Since they have been stated in 1890, the guidance of Koch’s postulates have been consciously 
or unconsciously used or adapted to establish causation in many diseases not related to 
bacterial infection [28], and it is notable that Koch’s postulates have been rationalized to 
explain the role of viruses in cancer [32]. Now, regarding their influence in cancer stem cell 
research, it is note worthy that if we replace the term “microorganisms” with the term “cancer 
stem cell” in the criteria presented Box 1, then the experimental procedure used to 
characterize cancer stem cells restate Koch’s postulates, as they have been used to identify the 
causative agent in an infectious disease such as tuberculosis (Fig 1B). Indeed, this finding is 
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not surprising since these postulates are now an implicit guideline for demonstrating causality 
in occidental biological medicine. As a matter of fact these experimental procedures have 
been successfully used for characterizing cancer stem cells in leukaemia and several solid 
tumors.  However, validation of the cancer stem cell paradigm through Koch’s criteria has 
also some limitations.  
 
Revisiting the cancer stem cell concept in the light of Koch’s postulates limitations. 
Limitations of Koch’s postulates in cancer research are similar to those observed for 
infectious diseases. For example, cell culture conditions used to expand cancer cells can select 
for cancer cells not representative to those found in the original tumor [33] or can be 
inadequate for maintaining some critical cancer cell subpopulations [34].  Koch’s postulates 
have also limitations when they are used in complex diseases with multi-causal chains. This 
has been described for polymicrobial diseases but is also evident in cancer research. For 
example, let us consider a tumor xenograft experiment with a cancer cell which requires two 
factors “x” and “y” for sustaining tumor growth (Fig 2). In Fig 2 A, the cancer cell produces 
both of these factors, and is therefore capable of supporting cancer growth. In this model, the 
“cancer stem cell” function is attributable to a cell entity, the cancer stem cell, which can be 
viewed as an infectious micro-organism or a pathogenic corpuscle. Here, the cancer stem cell 
fulfills Koch’s postulates, and this model squares with the germ theory of disease. In other 
words, the cancer stem cell is necessary and sufficient for sustaining tumor growth, and the 
“cancer stem cell” function is attributable to this cell entity. On the contrary, in Fig. 2B, the 
cancer cell is deficient in one factor. Therefore, cooperation between the cancer cell and 
another cancer or stromal cell is required for sustaining tumor growth [35]. In this model, 
each cell is necessary but not sufficient, and no individual cell fulfills Koch’s postulates. The 
“cancer stem cell” function is no longer attributable to a single cell entity or pathogenic 
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corpuscle but corresponds to a tumorigenic field ascribable to the tumor niche. In accordance 
with this model, accumulating evidence demonstrates that the stromal environment supports 
tumor growth and promotes invasion through, for example, stimulation of cancer cell 
proliferation or activation of angiogenesis [36-40]. Hence, in this model, cancer does not 
integrate well with the paradigm provided by Koch’s postulates. Indeed, a similar limitation 
of Koch’s postulates is found for polymicrobial infections that do not comply with Koch’s 
principles [30]. Accordingly, the success of Koch’s postulates in medical microbiology is due 
to the fact that most infectious diseases are monomicrobial. However, at the time of diagnosis, 
cancer is a complex multi-cellular disease containing multiple sub-clones [41,42]. 
Nevertheless, it must be noticed that the two models are not mutually exclusive. Regarding 
now the third postulate (transmission of disease by implantation of pathogen), it is related to 
the natural course of contagious diseases, and is therefore both experimentally and 
biologically relevant for these diseases. However, although viral infections contribute to 15-
20% of all human cancers [43], this disease is not usually considered as contagious. Thus, 
when considering the cancer stem cell concept, this postulate is experimentally valid since 
tumors can be serially transplanted in animals via cancer stem cell implantation, but it could 
be bio-logically questionable since cancer stem cells are not naturally contagious. In a sense, 
the experimental paradigm of tumor cell implantation does not replicate the original disease 
but only some of its symptoms. Some of them (tumor angiogenesis, hypoxia…) are 
biologically relevant as they reproduce the natural features of the disease. Accordingly, they 
produce valid concepts which in turn provide therapeutic breakthroughs such as anti-
angiogenic therapies. Other experimental features, such as the serial propagation of the 
disease through cell implantation in animals, although experimentally useful do not strictly 
belong to the natural course of the disease. Hence, their use for validating a concept such as 
the cancer stem cell concept could be debatable. Indeed, the missing evidence in the cancer 
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stem cell experimental paradigm is the cure of the natural disease following eradication of the 
experimentally defined “cancer stem cell”.  
 
 
Fig 2 
Tumorigenic corpuscle versus tumorigenic field. 
In A, “cancer stem cell” function is borne by a cell entity or corpuscle, the cancer stem cell, 
which experimentally is both necessary and sufficient for sustaining tumor growth. 
In B, (adapted from ref 35) “cancer stem cell” function is borne by a tumorigenic field made 
by the whole cancer cell environment (hormones, growth factors, extra-cellular matrix, cell 
interactions, angiogenesis, stromal cells…). Cancer cells are necessary but not sufficient. No 
single cancer cell fulfills the sufficiency criteria of a “cancer stem cell”, and stromal cells are 
potential valuable therapeutic targets. Moreover, microenvironment can contribute both 
positively or negatively to tumor growth [49-52]. Both models are supported by numerous 
experimental evidences and they are not mutually exclusive.  
 
Cancer stem cell: beyond Koch’s postulates. 
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Although parallels are often made between normal stem cell and cancer stem cell [44], the 
experimental paradigm used for characterizing cancer stem cells is also directly related to 
Koch’s principles. Questioning the fundamental limitations and validity of this guideline in 
cancer research is therefore required for designing novel experimental paradigms which are 
urgently need if we want to cure cancer. Thus, because of Koch’s postulates limitations, the 
very idea of cancer, as well as current experimental approaches, could be reconsidered on the 
basis of a new notion of causality going beyond the characterization of a transferable 
pathogenic entity as defined in the germ theory of disease. This can be viewed as an extension 
of the Paget’s “seed and soil” proposal [45]. In fact, the concept that tumorigenicity is driven 
by multicellular units, or cancer cell societies rather than by a special cell entity, is supported 
by numerous experimental evidence [18, 36-40].  Cancer has also been viewed as a problem 
of tissue organization in the tissue organization field theory (TOFT) [46,47]. All these 
different models suggest that in solid cancer, tumor growth is an emerging function not only 
sustained by rare cancer stem cell but also by the existence of a complex network of 
interactions generating a tumorigenic field [36-40, 45-48]. This complex network of 
interactions includes many non-tumoral cell types (fibroblasts, lymphocytes, macrophages, 
endothelial cells…) which are involved in the maintenance, the progression and the growth of 
the tumor [36-40,45-53]. This critical role of tumor environment does not exclude the 
existence in the tumor mass of cancer stem cells fulfilling Koch’s postulates and able to 
regrow a tumor outside of the tumor niche, since such cells have been experimentally 
characterized.  Nevertheless, these cancer stem cells should not be considered as the only 
cancer cells able to sustain tumor growth. Indeed, a recurrent question is to know if xenograft 
experiments does not select only the subset of cancer cells capable to engraft and to grow in 
the environment provided by the non-tumoral immunodeficient mice tissue where they are 
implanted [14,16,26].  Hence, the major drawback of the cancer cell implantation assay in 
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immunocompromised animals is that this assay can fail to detect human cancer cell 
populations unable to comply with Koch’s postulates but nevertheless capable to sustain 
tumor growth in patients [14,16,26].  
 
Towards new therapeutic paradigms. 
Another important point is that concepts from medical microbiology not only influence our 
way of reasoning through Koch’s postulates, but also govern our cancer therapeutic 
approaches. Thus, ablating infectious foci to limit microbial extension (tuberculosis 
lobectomy, amputation) is conceptually similar to tumor excision. Likewise, antimicrobial and 
anticancer chemotherapies which generally target individual causative agents are similar in 
their design and also their limitations. Indeed, emergence of bacterial strains resistant to 
available antibiotics is one of the current medical challenges just like drug-resistant cancer 
cells are. Targeting the microbiological niche, which also includes non-pathogenic host cells, 
is an alternative to present antimicrobial therapies. This could be done for example by 
targeting bacterial virulence rather than bacterial vital cellular processes [54]. Likewise, in 
cancer, anti-angiogenic therapies target stromal cells rather than cancer cells. Indeed more 
than 20 drugs targeting different cells in the microenvironment are currently in clinical trials 
for cancer [48,49].  Hence the possibility, after more than one century of Koch’s postulates 
hegemony, of resuming both infectious and cancer therapies into a “therapeutic field” 
unifying paradigm in which the sufficient and necessary pathogenic cell as defined in 
monomicrobial disease or in the cancer stem cell paradigm is no longer the only therapeutic 
target.  
 
Concluding remarks 
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Until the last century, humanity has been challenged with contagious disease as the leading 
cause of mortality. Hence, our current medical reasoning is profoundly influenced by views 
that originated from medical microbiology. The notion that cancer growth is maintained by a 
sub-population of particular cells, the cancer stem cells, is rooted in pathogen-centered views 
of microbial pathogenesis.  Industrial countries are now confronted with cancer as one of the 
leading causes of mortality. However, it is not sure that views born in the biological and 
historical context of monomicrobial infection are fully adequate for curing this disease which 
is often non-contagious and which requires interactions between both normal cells and 
genetically and epigenetically unstable cancer cell populations. Indeed, accumulating data 
suggest that therapeutic targeting must also include tumor microenvironment [40,49,50].  
Therefore, the possibility that Koch’s postulates act as a cultural archetype in cancer research 
should be considered. Indeed, the reductionist and oversimplified cancer stem cell paradigm 
which originates from the implicit application of Koch’s postulates should progressively 
evolve towards a “tumorigenic field” concept, just as the “one gene _ one protein _ one 
phenotype” paradigm has evolved towards epistasis [55]. This does not deny the importance 
of this guideline in the discovery of some fundamental aspects of cancer, such as the existence 
of oncogenic virus or the characterization of cancer cells with experimental stem-like features. 
However cancer research needs now to go beyond Koch’s postulates for opening the way to 
new experimental and therapeutic paradigms. 
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